Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks
Scott Fung(Toronto General Hospital), Marı́a Buti(Vall d'Hebron Hospital Universitari), Chi‐Yi Chen(National Taiwan University), Maciej Jabłkowski(Medical University of Lodz), Leland J. Yee(Gilead Sciences (United States)), Frida Abramov(Gilead Sciences (United States)), John F. Flaherty(Gilead Sciences (United States)), Hiroshi Yatsuhashi(Nagasaki Medical Center), Cheng‐Yuan Peng(China Medical University), Calvin Q. Pan(New York University), Dzhamal Abdurakhmanov(Sechenov University), Young‐Suk Lim(Asan Medical Center), Grace Lai‐Hung Wong(Chinese University of Hong Kong), Cihan Yurdaydın(Ankara University), Hongyuan Wang(Gilead Sciences (United States)), Yoon Jun Kim(Seoul National University), Tuan Nguyen, Sang Hoon Ahn(Yonsei University), Wai‐Kay Seto(State Key Laboratory of Synthetic Chemistry), Hie‐Won Hann(Fox Chase Cancer Center)
Cited by 14
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
|Proceedings of the National Academy of Sciences|2015|770
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484